Vinge advises Calliditas Therapeutics AB (publ) (“Calliditas Therapeutics”) in connection with the listing of the company’s shares on Nasdaq Stockholm’s main market. Trading in Calliditas Therapeutics’ shares on Nasdaq Stockholm commences today, 29 June 2018.
The price in the offering was set at SEK 45 per share, which corresponds to a value of the total number of shares in the company upon completion of the offering of SEK 1,593 million, assuming full exercise of the over-allotment option in the offering. Assuming full exercise of the over-allotment option, the value of the offering amounts to approximately SEK 747 million before transaction costs.
Calliditas is a specialty pharmaceutical company based in Stockholm, Sweden, focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications in which the company can partially or completely participate in the commercialization efforts. The company is focused on the development and commercialization of the product candidate Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy.
Vinge’s team primarily consists of Dain Hård Nevonen, Johan Larsson, Maria Schultzberg, Sofie Bjärtun, Sabina Kihlberg, Filip Öhrner, Victor Ericsson and William Kåge.